✓ Translated by DotMD AI Clinical Council Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #36409969 ↗

Phase III Randomized Trial: Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD) (N = 144)

Original Paper Title: “Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 144
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone.
  • Study Design & Sample: Phase III Randomized Trial published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (N = 144 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023), this phase iii randomized trial evaluating 144 human participants investigated: To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. Key clinical takeaway: CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023-03-01; N = 144; Rigor 88/100): CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: cannabidiol → Rx: cool-relief-gel-with-aloe → Rx: pain-relief-roll-on → Rx: advanced-eye-relief-eye-wash-water-solution → Condition: colorectal-cancer → Condition: adrenal-gland-cancer →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 36409969: Phase III Randomized Trial: Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD) (N = 144)

3 of 3 Free Questions Remaining